AI in Drug Discovery at a Glance The ongoing rise of artificial intelligence (AI) is significantly impacting various industries, with the pharmaceutical and biotech...
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) said it has completed a new artificial intelligence (AI) model to deliver the first clinically meaningful analysis of its...
David Harel, founder of CytoReason, tells the tale of every entrepreneur’s dream
Read more here.
Coinsmart. Europe’s Best Bitcoin and Crypto Exchange.Click Here
Platoblockchain. Web3 Metaverse Intelligence. Knowledge...
Pfizer will also have options to license the Israeli startup’s platform and disease models, and fund supplementary project support, in a deal potentially worth...
Poolbeg Pharma’s Jeremy Skillington talks to Proactive London after signing a deal with CytoReason, a leading artificial intelligence (AI) to provide AI analysis of Poolbeg’s influenza disease progression data derived from human challenge study samples. Watch the video here.
24 March 2022 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, has signed a deal with CytoReason , a leading artificial intelligence (AI) company developing computational disease models for efficient drug discovery and development, to provide AI analysis of Poolbeg’s […]
